Alvotech, Teva Pharmaceuticals and FDA
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also holds commercialization rights for AVT29 in the U.S.
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
The current health news highlights Abridge raising $250 million to boost AI medical documentation, layoffs involving ...
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback